Persian Persian
Nafas Journal,
Vol. 9 No. 1 (1401),
27 February 2022
Abstract
Abstract
Background and purpose: Patients with COVID-19 are at high risk of nosocomial bacterial and fungal infections due to risk factors such as hospitalization in the intensive care unit, mechanical ventilation and the use of broad-spectrum antibiotics. Data on the colonization of Candida species in patients with COVID-19 are very limited.
Material and method: A 57-year-old woman with diabetes and hypertension with acute respiratory distress syndrome (ARDS) due to COVID-19 infection referred to the emergency department of Dr. Masih Daneshvari Hospital in Tehran and after a long hospital stay in the intensive care unit and Several courses of antibiotic therapy with COVID-19 treatment protocol and mechanical ventilation, with candida colonization and antifungal therapy, despite partial satisfactory treatment, the patient died of cardiac arrest.
Conclusion: Candida species are the second most common fungal genus identified in fungal lung infections that affect hospitalized patients with COVID-19. Diabetes and COVID-19 are usually present as risk factors for fungal infections during a hospitalization. Because the widespread use of antibiotics and corticosteroids significantly predisposes a patient to fungal colonization and increased fungal load, which can lead to fungal infections. Therefore, early anti-fungal treatment and control of the source of colonization or infection can be one of the most important interventions to reduce the fungal load, which will bring better results with earlier treatment.
- Persian
- English
How to Cite
References
2. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 2020 Aug 1;81(2):266-75.
3. Al-Hatmi AM, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. Journal of Infection. 2021 Feb 1;82(2): e45-6.
4. Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, Hoenigl M. Covid-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? Journal of Fungi. 2020 Dec;6(4):211.
5. Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. 2017 Apr 3;8(3):352-8.
6. Rolling T, Hohl TM, Zhai B. Minority report: The intestinal mycobiota in systemic infections. Curr Opin Microbiol. 2020;56:1-6
7. Franquet T, Müller NL, Lee KS, Oikonomou A, Flint JD. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology. 2005 Jul;236(1):332-7.
8. Lim YK, Kweon OJ, Kim HR, Kim TH, Lee MK (2019) Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis 94(1):50–54. https://doi.org/ 10.1016/j.diagmicrobio.2018.11.014
9. Kiedrowski MR, Bomberger JM (2018) Viral-bacterial co-infections in the cystic fibrosis respiratory tract. Front Immunol 9:3067. https:// doi.org/10.3389/fimmu.2018.03067
10. Clancy, C.J.; Nguyen, M.H. COVID-19, superinfections and antimicrobial development: What can we expect? Clin. Infect. Dis.2020.
11. Segrelles-Calvo G, de S Araújo GR, Llopis-Pastor E, Carrillo J, Hernández-Hernández M, Rey L, Melean NR, Escribano I, Antón E, Zamarro C, García-Salmones M. Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and associated risk factors. Respiratory Medicine. 2021 Nov 1;188:106619.
12. Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: A narrative review. European journal of internal medicine. 2016 Oct 1;34:21-8.
13. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel medicine and infectious disease. 2020 Mar 1;34:101623.
14. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020 May 1;94:91-5.
15. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell metabolism. 2020 Jun 2;31(6):1068-77.
16. Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, Cornely OA, S Perlin D, Lass-Flörl C, Hoenigl M. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. Journal of Fungi. 2020 Jun;6(2):91.
17. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: We should be prepared. Journal de mycologie medicale. 2020 Jun;30(2):100971.
18. Magnasco L, Mikulska M, Giacobbe DR, Taramasso L, Vena A, Dentone C, Dettori S, Tutino S, Labate L, Di Pilato V, Crea F. Spread of carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically ill patients: one step back in antimicrobial stewardship?. Microorganisms. 2021 Jan;9(1):95.
19. Kauffman CA. Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults. UpToDate. http://www. uptodate. com/contents/clinical-manifestations-and-diagnosis-of-candidemia-andinvasive-candidiasis-in-adults. Accessed. 2018 Jun;27.
- Abstract Viewed: 212 times